The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

Andrea Gallamini, Sally F. Barrington, Alberto Biggi, Stephane Chauvie, Lale Kostakoglu, Michele Gregianin, Michel Meignan, George N. Mikhaeel, Annika Loft, Jan M. Zaucha, John F. Seymour, Michael S. Hofman, Luigi Rigacci, Alessandro Pulsoni, Morton Coleman, Eldad J. Dann, Livio Trentin, Olivier Casasnovas, Chiara Rusconi, Pauline BriceSilvia Bolis, Simonetta Viviani, Flavia Salvi, Stefano Luminari, Martin Hutchings

Research output: Contribution to journalArticle

Abstract

A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of 'interim' positron emission tomography performed during treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in patients with Hodgkin lymphoma; and (ii) the reproducibility of the Deauville five-point scale for the interpretation of interim positron emission tomography scan. Two hundred and sixty patients with newly diagnosed Hodgkin lymphoma were enrolled. Fifty-three patients with early unfavorable and 207 with advanced-stage disease were treated with doxorubicin, bleomycin, vinblastine and dacarbazine ± involved-field or consolidation radiotherapy. Positron emission tomography scan was performed at baseline and after two cycles of chemotherapy. Treatment was not changed according to the results of the interim scan. An international panel of six expert reviewers independently reported the scans using the Deauville five-point scale, blinded to treatment outcome. Forty-five scans were scored as positive (17.3%) and 215 (82.7%) as negative. After a median follow up of 37.0 (2-110) months, 252 patients are alive and eight have died. The 3-year progression-free survival rate was 83% for the whole study population, 28% for patients with interim positive scans and 95% for patients with interim negative scans (P

Original languageEnglish
Pages (from-to)1107-1113
Number of pages7
JournalHaematologica
Volume99
Issue number6
DOIs
Publication statusPublished - Jun 1 2014

Fingerprint

Hodgkin Disease
Positron-Emission Tomography
Dacarbazine
Vinblastine
Bleomycin
Doxorubicin
Multicenter Studies
Disease-Free Survival
Radiotherapy
Survival Rate
Drug Therapy
Therapeutics
Population

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. / Gallamini, Andrea; Barrington, Sally F.; Biggi, Alberto; Chauvie, Stephane; Kostakoglu, Lale; Gregianin, Michele; Meignan, Michel; Mikhaeel, George N.; Loft, Annika; Zaucha, Jan M.; Seymour, John F.; Hofman, Michael S.; Rigacci, Luigi; Pulsoni, Alessandro; Coleman, Morton; Dann, Eldad J.; Trentin, Livio; Casasnovas, Olivier; Rusconi, Chiara; Brice, Pauline; Bolis, Silvia; Viviani, Simonetta; Salvi, Flavia; Luminari, Stefano; Hutchings, Martin.

In: Haematologica, Vol. 99, No. 6, 01.06.2014, p. 1107-1113.

Research output: Contribution to journalArticle

Gallamini, A, Barrington, SF, Biggi, A, Chauvie, S, Kostakoglu, L, Gregianin, M, Meignan, M, Mikhaeel, GN, Loft, A, Zaucha, JM, Seymour, JF, Hofman, MS, Rigacci, L, Pulsoni, A, Coleman, M, Dann, EJ, Trentin, L, Casasnovas, O, Rusconi, C, Brice, P, Bolis, S, Viviani, S, Salvi, F, Luminari, S & Hutchings, M 2014, 'The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale', Haematologica, vol. 99, no. 6, pp. 1107-1113. https://doi.org/10.3324/haematol.2013.103218
Gallamini, Andrea ; Barrington, Sally F. ; Biggi, Alberto ; Chauvie, Stephane ; Kostakoglu, Lale ; Gregianin, Michele ; Meignan, Michel ; Mikhaeel, George N. ; Loft, Annika ; Zaucha, Jan M. ; Seymour, John F. ; Hofman, Michael S. ; Rigacci, Luigi ; Pulsoni, Alessandro ; Coleman, Morton ; Dann, Eldad J. ; Trentin, Livio ; Casasnovas, Olivier ; Rusconi, Chiara ; Brice, Pauline ; Bolis, Silvia ; Viviani, Simonetta ; Salvi, Flavia ; Luminari, Stefano ; Hutchings, Martin. / The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. In: Haematologica. 2014 ; Vol. 99, No. 6. pp. 1107-1113.
@article{c2b8672a242241ec8adcc85048a5d5c6,
title = "The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale",
abstract = "A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of 'interim' positron emission tomography performed during treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in patients with Hodgkin lymphoma; and (ii) the reproducibility of the Deauville five-point scale for the interpretation of interim positron emission tomography scan. Two hundred and sixty patients with newly diagnosed Hodgkin lymphoma were enrolled. Fifty-three patients with early unfavorable and 207 with advanced-stage disease were treated with doxorubicin, bleomycin, vinblastine and dacarbazine ± involved-field or consolidation radiotherapy. Positron emission tomography scan was performed at baseline and after two cycles of chemotherapy. Treatment was not changed according to the results of the interim scan. An international panel of six expert reviewers independently reported the scans using the Deauville five-point scale, blinded to treatment outcome. Forty-five scans were scored as positive (17.3{\%}) and 215 (82.7{\%}) as negative. After a median follow up of 37.0 (2-110) months, 252 patients are alive and eight have died. The 3-year progression-free survival rate was 83{\%} for the whole study population, 28{\%} for patients with interim positive scans and 95{\%} for patients with interim negative scans (P",
author = "Andrea Gallamini and Barrington, {Sally F.} and Alberto Biggi and Stephane Chauvie and Lale Kostakoglu and Michele Gregianin and Michel Meignan and Mikhaeel, {George N.} and Annika Loft and Zaucha, {Jan M.} and Seymour, {John F.} and Hofman, {Michael S.} and Luigi Rigacci and Alessandro Pulsoni and Morton Coleman and Dann, {Eldad J.} and Livio Trentin and Olivier Casasnovas and Chiara Rusconi and Pauline Brice and Silvia Bolis and Simonetta Viviani and Flavia Salvi and Stefano Luminari and Martin Hutchings",
year = "2014",
month = "6",
day = "1",
doi = "10.3324/haematol.2013.103218",
language = "English",
volume = "99",
pages = "1107--1113",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

AU - Gallamini, Andrea

AU - Barrington, Sally F.

AU - Biggi, Alberto

AU - Chauvie, Stephane

AU - Kostakoglu, Lale

AU - Gregianin, Michele

AU - Meignan, Michel

AU - Mikhaeel, George N.

AU - Loft, Annika

AU - Zaucha, Jan M.

AU - Seymour, John F.

AU - Hofman, Michael S.

AU - Rigacci, Luigi

AU - Pulsoni, Alessandro

AU - Coleman, Morton

AU - Dann, Eldad J.

AU - Trentin, Livio

AU - Casasnovas, Olivier

AU - Rusconi, Chiara

AU - Brice, Pauline

AU - Bolis, Silvia

AU - Viviani, Simonetta

AU - Salvi, Flavia

AU - Luminari, Stefano

AU - Hutchings, Martin

PY - 2014/6/1

Y1 - 2014/6/1

N2 - A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of 'interim' positron emission tomography performed during treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in patients with Hodgkin lymphoma; and (ii) the reproducibility of the Deauville five-point scale for the interpretation of interim positron emission tomography scan. Two hundred and sixty patients with newly diagnosed Hodgkin lymphoma were enrolled. Fifty-three patients with early unfavorable and 207 with advanced-stage disease were treated with doxorubicin, bleomycin, vinblastine and dacarbazine ± involved-field or consolidation radiotherapy. Positron emission tomography scan was performed at baseline and after two cycles of chemotherapy. Treatment was not changed according to the results of the interim scan. An international panel of six expert reviewers independently reported the scans using the Deauville five-point scale, blinded to treatment outcome. Forty-five scans were scored as positive (17.3%) and 215 (82.7%) as negative. After a median follow up of 37.0 (2-110) months, 252 patients are alive and eight have died. The 3-year progression-free survival rate was 83% for the whole study population, 28% for patients with interim positive scans and 95% for patients with interim negative scans (P

AB - A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of 'interim' positron emission tomography performed during treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in patients with Hodgkin lymphoma; and (ii) the reproducibility of the Deauville five-point scale for the interpretation of interim positron emission tomography scan. Two hundred and sixty patients with newly diagnosed Hodgkin lymphoma were enrolled. Fifty-three patients with early unfavorable and 207 with advanced-stage disease were treated with doxorubicin, bleomycin, vinblastine and dacarbazine ± involved-field or consolidation radiotherapy. Positron emission tomography scan was performed at baseline and after two cycles of chemotherapy. Treatment was not changed according to the results of the interim scan. An international panel of six expert reviewers independently reported the scans using the Deauville five-point scale, blinded to treatment outcome. Forty-five scans were scored as positive (17.3%) and 215 (82.7%) as negative. After a median follow up of 37.0 (2-110) months, 252 patients are alive and eight have died. The 3-year progression-free survival rate was 83% for the whole study population, 28% for patients with interim positive scans and 95% for patients with interim negative scans (P

UR - http://www.scopus.com/inward/record.url?scp=84901711760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901711760&partnerID=8YFLogxK

U2 - 10.3324/haematol.2013.103218

DO - 10.3324/haematol.2013.103218

M3 - Article

C2 - 24658820

AN - SCOPUS:84901711760

VL - 99

SP - 1107

EP - 1113

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 6

ER -